Elias Animal Health LLC
ELIAS Animal Health is dedicated to transforming cancer treatment for pets by applying state-of-the-art immunotherapy developed for humans. Their mission is to improve cancer treatment outcomes in veterinary patients through innovative therapies, including personalized cancer vaccines and T cell immunotherapy, with the goal of providing effective, less taxing treatment options for animals.
Industries
Nr. of Employees
small (1-50)
Elias Animal Health LLC
Products
Personalized autologous cancer immunotherapy for canine patients
A two-step therapeutic approach combining a personalized tumor-derived vaccine to prime tumor-specific T cells, followed by harvest, ex vivo activation/expansion, and reinfusion of the patient’s own activated T cells.
Personalized autologous cancer immunotherapy for canine patients
A two-step therapeutic approach combining a personalized tumor-derived vaccine to prime tumor-specific T cells, followed by harvest, ex vivo activation/expansion, and reinfusion of the patient’s own activated T cells.
Services
Production, processing, and quality-controlled release of personalized tumor-derived vaccines and activated autologous T-cell products, including logistics for sample transfer between clinics and facility.
Design and conduct of controlled clinical trials in canine cancer, including enrollment, protocol execution, adverse-event monitoring, and comparative outcome analysis.
Coordination and partnership with apheresis providers to enable clinical collection of immune cells from patients for downstream processing.
Production, processing, and quality-controlled release of personalized tumor-derived vaccines and activated autologous T-cell products, including logistics for sample transfer between clinics and facility.
Design and conduct of controlled clinical trials in canine cancer, including enrollment, protocol execution, adverse-event monitoring, and comparative outcome analysis.
Coordination and partnership with apheresis providers to enable clinical collection of immune cells from patients for downstream processing.
Expertise Areas
- Veterinary immuno-oncology
- Adoptive cell therapy development
- Autologous cell therapy manufacturing and scale-up
- Clinical trial design and execution for veterinary populations
Key Technologies
- Personalized tumor-derived vaccine
- Adoptive autologous T-cell therapy
- Apheresis-based cell collection
- Ex vivo T cell activation and numeric expansion
News & Updates
The USDA has approved ELIAS Cancer Immunotherapy (ECI®), a first-in-class treatment for canine osteosarcoma.
In vitro studies show that personalized T cell immunotherapy from ELIAS triggers a significant immune response against cancer cells.
The company is expanding its manufacturing capacity ahead of product approval and pipeline expansion.
Tammie Wahaus, CEO of ELIAS, discusses immunotherapy options for canine osteosarcoma on podcasts.
An overview of how immunotherapy trains immune cells to recognize and destroy cancer cells.
Resources and information for pet owners dealing with canine cancer, including the role of veterinarians and treatment options.
The USDA has approved ELIAS Cancer Immunotherapy (ECI®), a first-in-class treatment for canine osteosarcoma.
In vitro studies show that personalized T cell immunotherapy from ELIAS triggers a significant immune response against cancer cells.
The company is expanding its manufacturing capacity ahead of product approval and pipeline expansion.
Tammie Wahaus, CEO of ELIAS, discusses immunotherapy options for canine osteosarcoma on podcasts.
An overview of how immunotherapy trains immune cells to recognize and destroy cancer cells.
Resources and information for pet owners dealing with canine cancer, including the role of veterinarians and treatment options.